Cell adhesion affects carcinogenesis, tumor progression, and metastasis. We datamined a published transcriptome (GSE12452) of nasopharyngeal carcinoma (NPC) and identified SSX2IP as a significantly upregulated gene in NPC carcinogenesis among genes associated with cell adhesion (GO:0007155). Consequently, we assessed SSX2IP protein expression and its prognostic significance in 124 patients with NPC using immunohistochemistry and the H-score method. The status of SSX2IP immunoexpression correlated with clinical and pathological characteristics, as well as oncological outcomes. High levels of SSX2IP expression were significantly associated with more advanced primary tumor and TNM stages. Kaplan-Meier and log-rank analyses revealed that high levels of SSX2IP expression, and advanced tumor stage and lymph node metastasis were significantly associated with lower rates of local recurrence-free survival (LRFS), distant metastasis-free survival (DMeFS), and disease-specific (DSS) survival. Multivariate analysis showed that high levels of SSX2IP expression significantly predicted DSS (hazard ratio [HR], 4.290; 95% confidence interval [CI], 2.271-8.102; p < 0.001), DMeFS (HR, 4.159' 95% CI, 2.072-8.345; p < 0.001), and LRFS (HR, 3.007' 95% CI,: 1.418-6.378; p = 0.004). We associated high levels of SSX2IP immunoexpression with aggressive pathological features and worse oncological outcomes, suggesting its potential therapeutic value for patients with NPC.

中文翻译：

---

SSX2IP在鼻咽癌患者中的表达及其预后价值。

细胞粘附影响癌变，肿瘤进展和转移。我们对一份已发表的鼻咽癌（NPC）转录组（GSE12452）进行了数据挖掘，并将SSX2IP确定为与细胞粘附相关的基因（GO：0007155）中NPC致癌作用中的一个显着上调的基因。因此，我们使用免疫组化和H评分方法评估了SSX2IP蛋白的表达及其在124例NPC患者中的预后意义。SSX2IP免疫表达的状态与临床和病理特征以及肿瘤结局相关。高水平的SSX2IP表达与更晚期的原发肿瘤和TNM分期显着相关。Kaplan-Meier和对数秩分析表明，高水平的SSX2IP表达，晚期肿瘤分期和淋巴结转移与较低的局部无复发生存率（LRFS），远处无转移生存率（DMeFS）和疾病特异性（DSS）生存率显着相关。多变量分析表明，高水平的SSX2IP表达可显着预测DSS（危险比[HR]，4.290； 95％置信区间[CI]，2.271-8.102； p <0.001），DMeFS（HR，4.159'，95％CI，2.072- 8.345; p <0.001）和LRFS（HR，3.007'95％CI ,: 1.418-6.378; p = 0.004）。我们将高水平的SSX2IP免疫表达与侵略性病理特征和较差的肿瘤学结局联系起来，表明其对NPC患者的潜在治疗价值。多变量分析表明，高水平的SSX2IP表达可显着预测DSS（危险比[HR]，4.290； 95％置信区间[CI]，2.271-8.102； p <0.001），DMeFS（HR，4.159'，95％CI，2.072- 8.345; p <0.001）和LRFS（HR，3.007'95％CI ,: 1.418-6.378; p = 0.004）。我们将高水平的SSX2IP免疫表达与侵略性病理特征和较差的肿瘤学结局联系起来，表明其对NPC患者的潜在治疗价值。多变量分析表明，高水平的SSX2IP表达可显着预测DSS（危险比[HR]，4.290； 95％置信区间[CI]，2.271-8.102； p <0.001），DMeFS（HR，4.159'，95％CI，2.072- 8.345; p <0.001）和LRFS（HR，3.007'95％CI ,: 1.418-6.378; p = 0.004）。我们将高水平的SSX2IP免疫表达与侵略性病理特征和较差的肿瘤学结局联系起来，表明其对NPC患者的潜在治疗价值。